

Is 2 Weeks of Acetazolamide (500 mg) + Atomoxetine (100 mg) Daily Effective for Obesity Hypoventilation Syndrome Severity?

STUDY DESIGN


Randomized, double-masked crossover trial comparing **2 weeks of acetazolamide + atomoxetine with placebo** in 15 patients with obesity hypoventilation syndrome not treated with positive airway pressure therapy based on polysomnography and morning blood tests



Acetazolamide + atomoxetine compared with placebo results:

- ↓ Nocturnal & diurnal mean Pt_{CO_2}
- ↑ Apnea-hypopnea index (AHI) (median) -20.9 events/h (95% CI, -26.7 to -15.1)
- ↓ Mean nocturnal Sp_{O_2} 4.3% (95% CI, 2.8% to 5.7%)

RESULTS



In this proof-of-concept study, administration of acetazolamide + atomoxetine significantly improved sleep-related hypoventilation, oxygen parameters, and AHI in patients who were treatment-naïve with obesity hypoventilation syndrome.